SARANTIS S.A. (“the Company”) announces that, in implementation of the resolution of the Shareholders’ Annual General Meeting dated April 23rd 2024, the Company proceeded on October 18th 2024 with the purchase of 2,000 own shares at the average price of 11.
SARANTIS S.A. (“the Company”) announces that, in implementation of the resolution of the Shareholders’ Annual General Meeting dated April 23rd 2024, the Company proceeded on October 17th 2024 with the purchase of 3,000 own shares at the average price of 11.
SARANTIS S.A. (“the Company”) announces that, in implementation of the resolution of the Shareholders’ Annual General Meeting dated April 23rd 2024, the Company proceeded on October 16th 2024 with the purchase of 4,175 own shares at the average price of 11.
SARANTIS S.A. (“the Company”) announces that, in implementation of the resolution of the Shareholders’ Annual General Meeting dated April 23rd 2024, the Company proceeded on October 15th 2024 with the purchase of 6,669 own shares at the average price of 10.
SARANTIS S.A. (“the Company”) announces that, in implementation of the resolution of the Shareholders’ Annual General Meeting dated April 23rd 2024, the Company proceeded on October 14th 2024 with the purchase of 9,100 own shares at the average price of 10.
Sarantis Group has once again confirmed its strong presence in the pharmaceutical market by winning nine significant awards at the Best in Pharmacy Awards 2024. Organized for the 7th consecutive year in Greece by BOUSSIAS Events, these awards recognize outstanding performance in pharmacy products, creativity, and strategic marketing practices that promote these products in the market.
SARANTIS S.A. (“the Company”) announces that, in implementation of the resolution of the Shareholders’ Annual General Meeting dated April 23rd 2024, the Company proceeded on October 11th 2024 with the purchase of 4,934 own shares at the average price of 10.
SARANTIS S.A. (“the Company”) announces that, in implementation of the resolution of the Shareholders’ Annual General Meeting dated April 23rd 2024, the Company proceeded on October 10th 2024 with the purchase of 7,377 own shares at the average price of 10.